J. Ashley Jefferson

J. Ashley Jefferson

Auto-generated profile, based on publicly available information

J. Ashley Jefferson

Division of Nephrology, University of Washington, Seattle, Washington

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
PDF file
JJJ. Ashley Jefferson
J. Ashley Jefferson
SSStuart J. Shankland
Stuart J. Shankland

24 July 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
JJJ. Ashley Jefferson
J. Ashley Jefferson
Most glomerular diseases are immunologically mediated disorders of the kidney and are common causes of ESKD. In addition to supportive therapy, a wide range of immunosuppressive agents are used in the management of patients with these conditions. Immunosuppression requires a careful balance of risk and benefits, and many of these agents have a narrow therapeutic window and require close monitoring. This review describes the side effects of immunosuppressive agents used in recent randomized, controlled trials of glomerular disease, and highlights some of the key adverse events that determine the choice and prescription of these medications.

1 August 2013 in Kidney International
Verified
Journal Article
Open access
PDF file
JJJ. Ashley Jefferson
J. Ashley Jefferson
SSStuart J. Shankland
Stuart J. Shankland
A circulating permeability factor has long been implicated in the pathogenesis of primary focal segmental glomerulosclerosis (FSGS). Evidence in animal models and now in several cohorts of patients with primary FSGS suggests a role for the soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker and perhaps as a contributing factor. Confirmation of these findings might lead to new diagnostic and therapeutic strategies for FSGS as well as a better understanding of podocyte dysfunction.

4 June 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
SASyeda Behjat Ahmad
Syeda Behjat Ahmad
JJJ. Ashley Jefferson
J. Ashley Jefferson
Loss of tolerance and the production of self-reactive autoantibodies by the humoral immune system are central to the pathogenesis of many glomerular diseases. These antibodies are produced by plasmablasts and plasma cells, the end products of B-cell lineage development within the bone marrow and secondary lymphoid tissues. In addition to antibody production, B cells also present antigen to T cells and produce proinflammatory cytokines. Nontargeted immunosuppression has shown efficacy in glomerular disease but is associated with multiple side effects, and there remains a high proportion of patients with resistant disease. In this article, we will review the biology of antibody-secreting cells and focus on therapeutics that specifically target B cells and plasma cells. We will review B-cell depletion strategies, including anti-CD20 monoclonal antibodies, B-cell–activating factor, and a proliferation-inducing ligand inhibition and B-cell receptor inhibition, highlighting their role in different glomerular diseases and outlining reasons for therapeutic resistance. We will also review plasma cell–directed therapies including proteasome inhibition and anti-CD38 therapies and discuss novel treatments including chimeric antigen receptor-T therapy and bispecific T-cell engagers.

5 February 2013 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
JJJ. Ashley Jefferson
J. Ashley Jefferson
CACharles E. Alpers
Charles E. Alpers

15 October 2020 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AKAbbal Koirala
Abbal Koirala
JJJ. Ashley Jefferson
J. Ashley Jefferson